Immuneering (IMRX)

Executive Summary

Immuneering Corporation is a clinical-stage biotechnology company pioneering a novel therapeutic paradigm in oncology with its Deep Cyclic Inhibitors. The company's proprietary approach uses rhythmic, pulsed dosing of inhibitors targeting the MAPK pathway to outpace cancer's adaptive resistance mechanisms, aiming to improve durability of response and patient quality of life. Immuneering's lead candidate, IMM-1-104, is being evaluated in a Phase 1/2 trial for advanced solid tumors, including pancreatic adenocarcinoma, melanoma, and non-small cell lung cancer. The trial includes several combination arms with standard-of-care agents and checkpoint inhibitors. Additionally, the company has completed a Phase 1 trial for IMM-6-415, a second-generation Deep Cyclic Inhibitor. Immuneering went public via a SPAC merger in 2023 and trades on Nasdaq under the ticker IMRX. With a market capitalization of approximately $340 million, the company is positioned to deliver near-term clinical data that could validate its platform and drive significant value.

Upcoming Catalysts (preview)

• Q3 2026Clinical Data Update for IMM-1-104 in Pancreatic Cancer50% success
• H2 2026Presentation of Phase 1/2 Data for IMM-1-104 Combinations60% success
• Q4 2026Regulatory Guidance or Fast Track Designation for IMM-1-10440% success